Previous Section
Clinical Trials
1. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
- Author
- Laack E; Thom I; Krull A; Engel-Riedel W; Muller T; Meissner C; Durk H; Fischer J; Gutz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Gorn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C; Laack E; Thom I; Krull A; Engel-Riedel W; Muller T; Meissner C; Durk H; Fischer J; Gutz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Gorn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C;
- Institution
- University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Journal
- Lung Cancer. 2007 Aug;57(2):181-6. Epub 2007 Apr 17.
- Abstract URL
- Click here to view abstract
2. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
- Author
- Hesketh PJ; Chansky K; Israel V; Grapski RT; Mekhail TM; Spiridonidis CH; Mills GM; Kelly K; Crowley JJ; Gandara DR;
- Institution
- Caritas St. Elizabeth's Medical Center of Boston, Boston, Massachusetts 02135, USA. phesketh@massmed.org
- Journal
- J Thorac Oncol. 2007 May;2(5):440-4.
- Abstract URL
- Click here to view abstract
3. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.
- Author
- Ohyanagi F; Horiike A; Okano Y; Satoh Y; Okumura S; Ishikawa Y; Nakagawa K; Horai T; Nishio M;
- Institution
- Thoracic Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake 3-10-6, Koto-ku, Tokyo, 135-8550, Japan, mnishio@jfcr.or.jp.
- Journal
- Cancer Chemother Pharmacol. 2007 May 5;.
- Abstract URL
- Click here to view abstract
4. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis.
- Author
- Buchholz E; Manegold C; Pilz L; Thatcher N; Drings P;
- Institution
- Department of Surgery and Interdisciplinary Thoracic Oncology, Klinikum Mannheim, Mannheim, Germany. erika-buchholz@t-online.de
- Journal
- J Thorac Oncol. 2007 Jan;2(1):51-8.
- Abstract URL
- Click here to view abstract
5. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
- Author
- Gandhi L; Harding MW; Neubauer M; Langer CJ; Moore M; Ross HJ; Johnson BE; Lynch TJ;
- Institution
- Massachusetts General Hospital, Boston, Massachusetts, USA.
- Journal
- Cancer. 2007 Mar 1;109(5):924-32.
- Abstract URL
- Click here to view abstract
6. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
- Author
- Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S;
- Institution
- Department of Medicine, SUNY Upstate Medical University, Regional Oncology Center, 750 E Adams Street, Syracuse, NY 13210, United States. shahc@upstate.edu
- Journal
- Lung Cancer. 2007 Jul;57(1):84-8. Epub 2007 Mar 30.
- Abstract URL
- Click here to view abstract
7. Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
- Author
- Dy GK; Jett JR; Geoffroy FJ; Krewer KD; Tazelaar H; Maurer M; Rowland K; Mailliard J; Krook J; Dakhil S; Kutteh L; Kugler J; Wender D;
- Institution
- Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. Dy.Grace@mayo.edu
- Journal
- J Thorac Oncol. 2006 Mar;1(3):211-7.
8. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
- Author
- Hesketh PJ; McCoy J; Dunphy FR 2nd; Bearden JD 3rd; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR;
- Institution
- Caritas St. Elizabeth's Medical Center of Boston, Boston, MA 02135, USA. phesketh@massmed.org
- Journal
- J Thorac Oncol. 2006 Nov;1(9):991-5.
- Abstract URL
- Click here to view abstract
9. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
- Author
- Lara PN Jr; Chansky K; Davies AM; Franklin WA; Gumerlock PH; Guaglianone PP; Atkins JN; Farneth N; Mack PC; Crowley JJ; Gandara DR;
- Institution
- University of California, Davis Cancer Center, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
- Journal
- J Thorac Oncol. 2006 Nov;1(9):996-1001.
- Abstract URL
- Click here to view abstract
10. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
- Author
- Igawa S; Yamamoto N; Ueda S; Ono A; Nakamura Y; Tsuya A; Murakami H; Endo M; Takahashi T;
- Institution
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Journal
- J Thorac Oncol. 2007 Aug;2(8):741-4.
- Abstract URL
- Click here to view abstract
Next: Combination Therapies
